---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-080168"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:25:13.590399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A

## Summary
- Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.
- Part A enrolled 33 aggressive CRC patients and exceeded 20% overall response rate, triggering Part B.
- Primary endpoint of Part B is progression-free survival; enrollment expected ~12 months, data late 2024.
- Regained Nasdaq compliance with minimum bid price rule after 11 consecutive days above $1.00 (July 6, 2023).

## SEC filing metadata
- accession: 0001104659-23-080168
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/0001104659-23-080168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/tm2321081d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-080168
- JSON: https://secwatch.observer/filing/0001104659-23-080168.json
- Plain text: https://secwatch.observer/filing/0001104659-23-080168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.